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ADHERENCE TO MEDITERRANEAN STYLE DIETARY PATTERN AND 
TOTAL CANCER RISK IN THE FRAMINGHAM OFFSPRING COHORT STUDY 
IOANNA YIANNAKOU 
 
ABSTRACT 
Background: The benefits of the Mediterranean-style dietary pattern in mitigating 
cancer risk among Americans is unclear and its role in obesity-related cancer risk 
has not been evaluated. 
 
Objectives: This study examines the prospective association between adherence 
to a Mediterranean style dietary pattern and cancer risk (including total, obesity 
related, breast and colorectal cancers) among men and women in the Framingham 
Offspring (FOS) cohort.  In secondary analyses for breast cancer, we explore 
stratifying by hormone receptor status and menopausal status. 
 
Methods: The Mediterranean style dietary pattern (MSDP) score was derived from 
a semi-quantitative food frequency questionnaire taken at examination visit 5 in 
the prospective FOS cohort. Subjects included 3199 participants (1703 women 
and 1496 men), aged 30 years old and older, who were free of prevalent cancer. 
The MSDP score was classified into tertiles and also dichotomized (MSDP score 
<19 vs. ≥19) to evaluate the association between the MSDP and cancer risk 
through the ninth examination cycle (2014). Cox proportional-hazards regression 
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models were used to estimate hazard ratios (HRs) and 95% confidence intervals 
(CIs) for all subjects and for men and women separately, adjusting for confounding 
by age, physical activity, body mass Index, pack-years of cigarette smoking, 
supplement use, diabetes status and sex (for all subjects models). In the breast 
cancer model, we adjusted for age, waist-to-height ratio height ratio, pack-years, 
physical activity, diabetes, supplement use age at menopause. Factors 
 found not to confound the effects of the MSDP on cancer risk were excluded from 
final models. 
 
Results: During a median follow-up of approximately 18 years, 377 and 273 
cancer cases were documented among men and women, respectively. Women in 
the upper two tertiles of the MSDP score had approximately 30% lower lower total 
cancer risks than women in the lowest tertile (tertile 2: HR, 0.69, 95% CI: 0.50-
0.94; tertile 3: HR, 0.73; 95% CI: 0.54-0.99). Effects in men were weaker. Higher 
adherence to a MSDP was somewhat more strongly protective against total cancer 
risk among lower-risk individuals such as those who were leaner (BMI <25), drank 
less alcohol (<14 g/d), and did not currently smoke cigarettes. The association 
between MSDP adherence and total cancer risk was also modified by waist 
circumference and WHtR. We also observed a non-statistically significant 
protective effect of higher MSDP conformity and obesity-related cancer risk (tertile 
3: HR, 0.80, 95% CI: 0.60-1.07). The association was present especially among 
women (tertile 2: HR, 0.76, 95% CI 0.53-1.09; tertile 3: HR, 0.73, 95% CI: 0.51-
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1.05). In analyses of effect modification by anthropometric measures of body fat, 
the combined effect estimates for higher adherence to the MSDP in women and 
body fat were more than additive for BMI and WHtR. The MSDP adherence was 
also inversely associated with BrCa risk (tertile 3 vs tertile 1: HR: 0.58, 95% CI: 
0.34-0.98) especially in post-menopausal women (HR: 0.51, 95% CI: 0.29-0.91) 
and among those with any positive Estrogen Receptor/Progesterone Receptor 
BrCa (HR: 0.58, 95% CI: 0.31-1.06). We found no association between MSDP and 
colorectal cancer in these analyses.   
 
Conclusions: In this large cohort study, higher adherence to MSDP was 
associated with lower cancer risk (including total, obesity-related and breast 
cancers), among women aged 30 years old or older in the FOS study.  
 
Keywords: cancer risk, breast cancer risk, obesity related cancer, post-
menopause, breast cancer subtypes, Mediterranean diet, epidemiology   
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INTRODUCTION  
 
Cancer incidence 
Cancer is a major public health problem worldwide, with approximately 440 new 
cases per 100,000 people per year during 2011–2015 1,2. While cancer death rates 
have decreased by 25% between 1990 and 2014 and survival increased, cancer 
is still the second leading cause of death in the United States (US) 3,97. Breast 
cancer (BrCa) is the second most commonly diagnosed tumor worldwide, with 67.5 
cases per 100,000 diagnosed among women in the US97 (2011-2015). One out of 
7 women in the US will develop BrCa during her lifetime. The fourth most frequently 
diagnosed cancer is colorectal (CRC), with 39.4/100,000 new cases occurring in 
2011-2015 in the US. Overall, the global cancer burden is influenced by both 
modifiable and non-modifiable risk factors. Genetic factors are thought to explain 
approximately 5-10% of overall cancer cases while the remaining 90-95% cases 
of carcinogenesis are likely attributable to environmental and lifestyle factors 4. In 
the US, approximately 30–35% of cancer-related deaths have been attributed to 
diet, 10-20% to obesity, and 4-6% to alcohol, while tobacco, infections, and other 
factors are estimated to cause 25–30%, 15–20%, and 10–15%, respectively 5. 
Given the large burden of cancer contributing to premature death worldwide and 
the relevant many potentially modifiable risk factors, it is essential that we prioritize 
prevention measures in order to decrease the burden of this major chronic disease. 
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Obesity-related cancers 
According to the World Health Organization (2018), the prevalence of obesity has 
nearly doubled since 1975. In 2016, 67.9% of U.S. adults were overweight (defined 
as having a body mass index [BMI] of 25-29.9 kg/m2) and 36.2% were obese (BMI 
≥30 kg/m2). A preponderance of the evidence suggests that obesity has an 
extensive influence on cancer risk 6. Excess body fat including overweight, obesity 
and weight gain (during middle adult years) are strong modifiable risk factors for 
certain cancers including breast (post-menopausal), colorectal, endometrium, 
gallbladder, oesophageal, gastric, kidney, thyroid, leukaemia and pancreas 6,7. 
Overweight- and obesity-related cancers constituted 40% of all cases diagnosed 
in 2014 8. In particular, post-menopausal BrCa, which accounts for 31% of all 
cancers, was the most frequently-occurring obesity-related cancer in 2015 as well 
as the most frequently studied cancer type in general. The Million Women Study 
in the UK including 45,037 cancer cases followed for 5.4 years, found that obese 
women (vs. lean with BMI 22.5-24.9kg/m2) had a nearly 30% higher risk of 
developing postmenopausal BrCa (Relative risk (RR), 1.29; 95% Confidence 
Interval (CI): 1.22-1.36)9. Previous evidence suggests that obesity was associated 
with a 30-70% increased risk of CRC compared with normal-weight people9. 
Finally, data for 3850 subjects in the Framingham Offspring Study (2018) found 
that gaining ≥0.45 kg (≥1.0 pound) per year than (vs. having stable weight) over 
~14 years of follow-up increased the risk of overweight-obesity related cancers by 
38% (95% CI: 1.09-1.76) 10. 
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The association between obesity and cancer risk may result from the pro-
inflammatory effects of excess adiposity or from the lifestyle factors such as diet 
that promote obesity. The average American consumes excess calories and has 
low energy expenditure. Based on the Dietary Guidelines, 2015-2020, Americans 
consume fewer vegetables, fruits, legumes, whole grains and seafood than the 
recommended intake ranges and more refined gains, added sugars and saturated 
fat. This so-called Western dietary pattern, combined with a sedentary lifestyle, 
could partly underpin the relationship between obesity and cancer incidence 11.  
 
The link between cancer, inflammation, and obesity 
The mechanistic links between obesity and cancer have been extensively 
reviewed 3,6,12–18 and will be briefly summarized below. Figure 1 illustrates the links 
between obesity and inflammation, adipokine production, altered sex steroid 
metabolism, and insulin secretion.  
 
1. Inflammation: Obesity, especially visceral obesity, is linked with low-grade 
systematic inflammation 6,16. Excess nutrients lead to the expansion of 
adipose depots via growth of adipocytes to store triglycerides. When the 
capacity of individual adipocytes is exceeded they undergo apoptosis, 
recruiting macrophages to the tissue and driving their activation in order to 
remove the dying cells. Activated macrophages produce pro-inflammatory 
cytokines such as Interleukin-6 (IL) and tumor necrosis factor alpha (TNF-
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α) that have been connected with the development and progression of 
cancers. TNF-α drives activation of the transcription factor Nuclear Factor 
Κβ (NF-κB), which regulates the activation of hypoxia-inducible factor-1a 
(HIF-1A), cyclooxygenase 2 (COX-2), transcription factor 3 (STAT3), IL-1 
and IL-6 and can promote cell survival, proliferation, and metastasis. 
Additionally, IL-6 activates STAT3, which has been found to be activated in 
a number of cancers, thereby promoting cell survival. NF-κB is 
overexpressed in cancer cells along with COX-2 which is essential to 
produce eicosanoids (prostaglandins and leukotrienes)6. This inflammatory 
state combined with excess nutrients can also drive the production of 
reactive oxygen species (ROS) which can damage Deoxyribonucleic Acid 
(DNA) and drive mutagenesis 19. 
 
2. Adipokines such as leptin released from adipose tissue were investigated 
to stimulate cancer cell proliferation (including breast and colon) through 
activation of mitogen-activated protein kinases (MAPKs) and signaling 
STAT3 and extracellular regulated kinase pathways 6,20. Also, adiponectin 
has been found to inhibit colon cancer growth through decreasing 
mammalian target of rapamycin (mTOR) and Jun N-terminal kinases (JNKs) 
phosphorylation6.  
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3. Insulin Signalling: Obese people tend to have hyperinsulinemia, likely due 
to insulin resistance and increased insulin growth factor 1 levels (IGF-1) 3. 
Insulin has been reported to favor cancer development via activation of 
Phosphoinositide 3-kinase (PI3K), extracellular signal-regulated kinases 
(ERK) pathways and up-regulation of IGF-1 which can further activate 
downstream of PI3K and ERK that are associated with cancer development 
16. IGF-1 also promotes BrCa cell proliferation via its transactivation of the 
leptin receptor 6.  
 
4. Sex Hormones: Obesity is linked with increased levels of estradiol in the 
blood in post-menopausal women. The enzyme responsible for converting 
androgens to oestradiol, aromatase, is highly expressed in adipose tissue, 
potentially underlying this association. Oestradiol can stimulate the 
proliferation of breast epithelial tissue 6,13 
  
Figure 1: The interplay between obesity, inflammation, and cancer6,19. Abbreviations: TNF-a: tumour necrotic 
factor a; NF-Κβ: nuclear factor κΒ; HIF-1A: hypoxia-inducible factor-1a; COX-2: cyclooxygenase 2, STAT3: 
Signal transducer and activator of transcription; IL-1: Interleukin 1; MAPKs: mitogen-activated protein kinases; 
mTOR: mammalian target of rapamycin; JNKs: Jun N-terminal kinases;  PI3K: Phosphoinositide 3-kinase; 
ERK: extracellular signal-regulated kinases; IGF-1: Insulin growth factor 1 level;  (+) activates; (-) Inhibition
6
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The importance of studying dietary indices 
It has been estimated that over the past decade,  25% of cancer cases could be 
prevented by reducing obesity and improving health behaviors such as diet and 
physical activity3. Diet has been extensively studied in the etiology of BrCa and 
CRC; however, the evidence linking specific foods and nutrients with cancer risk 
is rather weak and heterogeneous, apart from the evidence about the adverse 
effects of increased alcohol intake on cancer risk 21–23. This inconsistency might 
be partly explained by the fact that individuals do not consume single foods or 
nutrients, but rather a mixture of foods containing nutrients and non-nutrient 
components that may interact interdependently or antagonistically. For example, 
single nutrients may exert pronounced health effects when combined with other 
nutrients/foods in a dietary pattern but not when consumed alone. Thus, assessing 
the overall dietary patterns may provide stronger evidence for understanding the 
impact of dietary factors on cancer risk 14,24–26.  
 
Evidence on the role of dietary patterns on cancer risk is still limited. The latest 
report by the American Institute for Cancer Research (2018) and the American 
Cancer Society (2004) recommends a healthy dietary pattern rich in fruits, 
vegetables, legumes, and whole grains, while limiting consumption of added 
sugars, red and processed meats. Many of these recommendations are 
incorporated into the Mediterranean Style Dietary Pattern (MSDP)93. MSDP has 
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been recommended by the US Dietary guidelines 2015-2020 as one of the Healthy 
Style Eating Patterns 11.  
 
The Mediterranean diet (MD) 
Historically, populations living in the geographic area of the Mediterranean Sea 
have had a lower incidence of cancer compared with those living in northern 
Europe and the US, and this has been mainly attributed to a healthier dietary 
pattern (the MSDP) 3,15,27. The traditional Mediterranean diet that was initially 
developed in the 1960s reflects the dietary habits of the inhabitants of 
approximately 16 countries bordering the Mediterranean Sea including Greece 
and Southern Italy 18. The MSDP has been long described as a well-balanced 
plant-based diet; however, there is no explicit pattern due to the variations in 
culture, religion, ethnicity, and social-economic status among and within the 
different Mediterranean countries 6,15,28. For example, Greeks consume a high 
amount of fish whereas the Italian diet is high in pasta consumption. Despite the 
above dietary variability, the diet in Crete prior to1960 has been acknowledged as 
the model of a traditional MSDP as illustrated in the Greek MD pyramid (Figure 2). 
The Cretian diet is characterized by higher intakes of plant-based foods such as 
vegetables, fruits, legumes, nuts, and non-refined cereal and grain products (e.g., 
whole grains). Fish and poultry are consumed in moderation whereas consumption 
of red and processed meats, high-fat dairy products, refined grains, and sweets 
are limited. Olive oil and olives are the most common sources of fat, and thus the 
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monounsaturated fatty acid:saturated fatty acid (MUFA:SFA) ratio is relatively 
high. Finally, moderate intake of red wine during meals and increased physical 
activity are important components of the MSDP  4,6,94.  
 
Figure 2: The Greek MD pyramid94 
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Mediterranean diet and overall cancer risk 
Since early 1990, the MSDP has been investigated with respect to overall mortality 
and lifespan in Greece 29 and other Mediterranean countries 30. A growing body of 
scientific evidence has since emerged and reported on health benefits of 
adherence to MSDP in the reduction of all-cause mortality 23 as well as in the 
primary and secondary prevention of non-communicable chronic diseases, such 
as cardiovascular disease; neurodegenerative disease, type 2 diabetes mellitus, 
neoplastic diseases 15,18,31 among Mediterranean and non-Mediterranean 
populations. Using data from Trichopoulou et al it has been estimated that up to 
25% of new CRC cases and 15% of BrCa cases could be prevented if the 
populations (with high-incomes and typical Western diets) shifted to a traditional 
healthy MD 32,33. Several recent epidemiological studies support the cancer-
protective effect of MSDP adherence, especially for overweight-obesity related 
cancers. To date, there have been four meta-analyses in the last four years 
investigating adherence to a MSDP and cancer mortality and/or incidence. First, 
Sofi et al utilized data from prospective cohort studies, and found that every 2-point 
increase in the MSDP adherence score was associated with a 6% lower cancer 
risk or mortality (summary RR 0.94; 95% CI:  0.92-0.96)34. Schwingshackl & 
Hoffmann reported a statistically significant 10% pooled risk reduction for overall 
cancer mortality/ incidence (cohort RR: 0.90; 95% CI 0.86-0.95) comparing highest 
vs. lowest MSDP adherence. The heterogeneity (I2) of 55% across studies was 
lower than in more recent studies 27. Another meta-analysis by Schwingshackl & 
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Hoffmann in 2015 included 14 cohort studies and found that the highest adherence 
to a MD diet was associated with a much lower risk of total cancer mortality (RR: 
0.87, 95% CI 0.81-0.93, I2 = 56%) 35. Finally, Schwingshackl et al published a 
similar meta-analysis including more recent cohort studies in which they confirmed 
that highest adherence to MSDP was inversely associated with cancer mortality 
risk (RR: 0.86, 95% CI 0.81-0.91). However, the heterogeneity across studies was 
higher (I2=82%) 36. Thus, while there is some epidemiological evidence that a 
MSDP may play a protective role in the incidence of total cancer, the evidence on 
the risk of different types of cancer such as breast and colorectal is still limited.  
 
Mediterranean diet and Breast Cancer 
Higher conformity to a MSDP has been associated with lower rates of BrCa in 
many observational studies but differences in risks were noted between molecular 
subtypes (defined by hormone receptor status) and by menopausal status. Other 
studies did not have sufficient data to support such an observation.  
 
In 2017, Schwingshackl et al pooled data from seven cohorts and observed that 
adhering to a MSDP was associated by 6% lower risk of BrCa (RRcohort=0.94, 95% 
CI:0.90-0.99); heterogeneity in this study was very low (I2=8%)36. However, 
beneficial effects of high adherence to a MSDP (vs lowest MSDP) were observed 
only among post-menopausal women (RR=0.92; 95% CI:0.86-0.99) and not 
among pre-menopausal women (RR=1.03, 95% CI:0.75-1.42). These results were 
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inconsistent with those reported by Cade et al in which maximal adherence to 
MSDP was associated with lower BrCa risk (Hazard Ratio (HR) =0.65, 95% 
CI:0.42-1.02) among pre-menopausal but not post-menopausal women (HR=1.30, 
95% CI:0.83-2.05) 37. The EpiGEICAM case-control study found an inverse 
association in both subgroups38. Overall, most of the studies 38–40 concluded that 
MSDP seems to be more protective against post-menopausal BrCa, a finding that 
could be attributed to the role of estrogen metabolism in modulating the effects of 
nutrition on BrCa risk in pre- and post-menopausal women.  
 
BMI and body fatness have been shown to influence the risk of BrCa differently in 
pre- and post-menopauseal women41,42. For example, higher body fat lowers the 
risk of pre-menopausal BrCa while the post-menopausal BrCa risk is found to be 
higher. While the use of hormone replacement therapy may modify these effects, 
such evidence is still limited 36. Further research is warranted to understand 
whether the effects of body fat on BrCa risk are modified by menopausal status. 
 
Other studies examined the effects of MSDP adherence on the risks of BrCa 
subtypes and inconsistent results were reported. On one hand, a meta analysis 36 
and individual epidemiological studies 43,44 demonstrated no association of MD 
adherence on any positive ER/PR BrCa risk, but lower risks were seen in ER-/PR- 
BrCa. On the other hand, few studies reported an association of higher conformity 
to MSDP and lower incidence rate of ER+/PR+ BrCa24,41,45.  A possible biological 
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rational about the beneficial MSDP effects on this ER+BrCa subtype is that the 
estrogen metabolism is involved and some nutrients in the MSDP has been 
investigated to reduce endogenous estrogen production and increase sex-
hormone binding globulin levels, thus decreasing the circulating levels of estrogen 
and as a result, reducing the risk of BrCa41. However, the MSDP consists of a 
combination of foods and nutrients, and therefore it is difficult to elucidate if the 
effects of MSDP on BrCa differ by molecular BrCa subtypes 41. Overall, the findings 
on MSDP and risks of BrCa subtypes, are based on a limited number of studies 
with very small sample sizes, and thus further studies are warranted.  
 
Few investigators reported no association between MSDP and risk of BrCa. For 
example, in meta-analyses by Schwingshackl et al the authors found no 
association between higher conformity to MSDP and risk of BrCa 27,35. Similarly, in 
a case-control study, Pot et al reported that MSDP was not related with BrCa risk 
(Odds Ratio (OD)=1.05, 95% CI: 0.77-1.43) 6. To date, there is only one 
randomized clinical trial, the PREDIMED study, with more promising results on the 
effects of MD in the prevention of post-menopausal BrCa 25. Toledo et al recruited 
4152 women with high cardiometabolic risk and randomly allocated them to the 
following three trial arms: 1) MD group supplemented with extra virgin olive oil; 2) 
MD with mixed nuts or 3) low-fat diet (the control group). The “MD+ olive oil” and 
“MD+ nuts” groups had 68% (95% CI: 0.13-0.79) and 41% (95% CI 0.26-1.35) 
lower risk of post-menopausal BrCa, respectively, compared with the control 
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group. One major limitation of this study lies in the fact that the incident BrCa cases 
were few (n=35) and analyses were not stratified by molecular BrCa subtypes.  
 
Mediterranean diet and Colorectal cancer 
Cancer-protective effects of MSDPs on CRC have been consistently reported in 
the consecutive meta-analyses by Schwingshackl et al 27,35,36. The highest MSDP 
score was associated with 14% lower risk of CRC in the pooled cohort studies 
(RR=0.86, 95% CI:0.80-0.92) and 29% reduced risk across case-control studies 
(RR=0.71, 95% CI: 0.57-0.88) 27. In other studies, differences were noted between 
men and women as well as between anatomic locations such as distal, proximal 
colon and rectum. Some observational studies demonstrated stronger inverse 
relations between MSDP and risk for rectal cancer than colon cancer. A 2-point 
increase in the MSDP score resulted in a 31% reduced risk of rectal cancer but 
only a 6% reduction in colon cancer46. These differential results were consistent in 
other case-control and cohort studies 47–49. However, a pooled analysis of three 
Italian case control-studies found stronger risk reductions for the proximal colon 
(OR=0.48, 95% CI:0.32-0.73) compared with rectum (OR=0.58, 95% CI:0.44-
0.75). Other studies found that a 2-point increase in the MSDP score was not 
associated with cancer of either the rectum 50 or proximal colon 46. These 
differential effects between anatomical subsites could be owing to the 
methodological limitations across studies (e.g., small subsite numbers leading to 
low statistical power) but might also be due to the variation in microbial gut mucosa 
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or molecular and biochemical composition (e.g., pH) throughout the colon 51. In 
addition, the literature shows that effects of the MSDP on colorectal cancer risk 
tend to be stronger in men than women 49,52, suggesting that genetic and 
epigenetic factors could play a role in the link between MSDP and colorectal 
carcinogenesis. Overall, while most studies found a protective effect of the MSDP 
on total CRC risk47, further research is needed to better understand how these 
effects may differ by sex and anatomic location. 
 
Cancer protective effects of dietary components in MSDP 
MSDP is rich in polyphenols, phytochemicals, carotenoids, flavonoids, resveratrol, 
fiber, and its fatty acid profile is high in omega-3 and MUFA. This overall nutrient 
profile is thought to have antioxidant, anti-inflammatory, antiproliferative and anti-
mutagenic properties (Figure 3) 3,4,6,18,19,25,28,53. In addition, the high fiber, 
polyphenols and MUFA content, as well as the consumption of plant-based foods, 
could explain some of the obesity protective effects of MSDP on cancer 
development (Kwan et al., 2017). However, there is not enough evidence to 
establish that conformity to a MSDP helps to reduce weight gain which can then 
lower cancer risk. 
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Figure 3: The potential cancer-protective mechanism of the traditional MSDP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polyphenols 
Polyphenols are a diverse class of plant-derived compounds found in citrus fruits, 
berries, onions, legumes, whole grains, tea, red wine, and olive oil, all highly 
consumed as part of the MSDP. Figure 4 describes the mechanisms underpinning 
the antioxidant and anti-inflammatory properties of different phenolic compounds 
on BrCa and CRC 19. Oleuropein and hydroxytyrosol, polyphenols found in olive 
oil, as well as resveratrol from red wine have been found to inhibit COX1, COX2, 
and lipoxygenase (LOX). Reductions in COX activity reduce the levels of 
arachidonic acid, leukotrienes, prostaglandins, and fatty acids derived 
inflammatory mediators that can promote tumorigenesis 54. Human and animal 
studies showed that various flavonoids including quercetin and others in olive oil 
are able to intervene with the function of cytokines (TNF-a, IL-1 IL-6) and therefore 
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exert anti-inflammatory properties. Polyphenols also act as radical scavengers and 
were investigated to suppress nitric oxide synthase (NOS) enzymes resulting in 
reduced nitric oxide (NO) production. Polyphenols, especially quercetin, have 
been found to decrease the activity of  MAPKs, which are crucial for tumor 
proliferation and growth in human cells via inhibition of ERK , JNK, and TNF-a6. 
Additionally, Quercetin reduces oxidative stress and cell proliferation and 
increases autophagy through suppression of mTOR 55, potentially preventing the 
progression of cancers. Resveratrol exerts similar effects through the induction 
and activation of the transcription factor SIRT1 associated with caloric restriction 
56 (not shown on the diagram) respectively. Also, nuts containing phytic acid and 
resveratrol have been reported to influence processes essential to carcinogeneses 
such as angiogenesis, apoptosis, and invasion 13. Although these effects were 
supported by animal and some epidemiological studies, several intervention trials 
have failed to confirm these findings, possibly due to differences in microbiota, the 
food matrix and enzymes in the gastrointestinal tract that can affect the 
bioavailability of polyphenols 19,51. 
  
Figure 4: The biological plausibility of the anti-inflammatory effects of polyphenols on the risk of CRC and BrCa. 
Abbreviations: NOS: nitric oxide synthase; NO nitric oxide; COX-2: cyclooxygenase 2; MAPKs: mitogen-activated 
protein kinases; mTOR: mammalian target of rapamycin; NF-Κβ: nuclear factor κΒ. 
1
8
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Fiber 
The MSDP is characterized by a high intake of whole grains, legumes, fruits and 
vegetables and low intake of refined cereals; therefore the fiber content in the 
MSDP is high. Fiber has been found to increase stool bulk and reduce transit time 
and thus decrease the exposure time of colorectal mucosa to potential fecal 
carcinogenic compounds 6. Furthermore, the short chain fatty acids produced from 
the fermentation of fiber such as butyrate could also play a role in its protective 
effects on CRC19. In addition, whole grains and legumes rich in fiber with low-
glycemic index, could increase satiety and help with weight loss6,19. A low glycemic 
index could also avoid the post-prandial rise in glucose levels, perhaps improving 
insulin resistance and reducing IGF-1 which can stimulate carcinogenesis. 
Evidence from a meta-analysis suggests that 10gr daily of dietary fiber could result 
in more than 10% reduction in CRC risk (95% CI 0.86-0.94) 57. 
Olive oil 
The cancer protective properties of olive oil are suggested to result from the high 
content (70-80%) of oleic acid which is a MUFA. Oleic acid was found to reduce 
pro-inflammatory molecules, downregulate COX 2 and HER-2 oncogene which is 
a tumor marker in BrCa cells 6. The phenolic content of olive oil and its effects are 
described above and demonstrated in figure 4. Extracted olive oil as well as lignans 
in olive oil were found to inhibit carcinoma of the breast and colon, perhaps owing 
to their antioxidant capacity. In epidemiological studies, the effects of olive oil on 
risk of BrCa and CRC are inconsistent. In the PREDIMED trial, the groups with MD 
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supplemented with extra-virgin olive oil or nuts compared to low-fat diet were found 
to have reduced levels of inflammatory cytokines such as IL-6 (which is associated 
with tumorigenesis) 25. However, in the EPIC study, olive oil was not associated 
with the risk of ER+/PR+, but negatively associated with ER-/PR- tumors 30. 
Essential fatty acids 
Linoleic acid (LA) (18:2, n-6), the shortest-chain omega-6 PUFA, is found in eggs, 
poultry, wholegrain bread, and vegetable oils. Alpha-Linolenic acid (ALA) the major 
omega-3 PUFA, is found in fatty fish, walnuts and leafy green vegetables which 
are commonly consumed in the MSDP. These essential fatty acids could be 
converted to different eicosanoids (prostaglandins and leukotrienes) that exert 
different effects on cancer progression and development 6. For example, 
arachidonic acid derived from LA has been found in some studies to produce pro-
inflammatory eicosanoids whereas eicosapentaenoic acid derived from LNA 
produces anti-inflammatory ones. However, Klein et al found no association 
between omega 6 or omega 3 fatty acids and breast cancer risk58. Neverthless, in 
another study, omega three fatty acids have been found to be inversely associated 
with BrCa and CRC due to suppression of pro-inflammatory eicosanoids from 
omega-6, inhibition of angiogenesis, COX2, and NF-kB, as well as a 
transformation of neoplastic cells19. Meta-analyses showed that fish consumption 
was associated with 12% reduced risk of CRC (OR=0.88, 95% CI: 0.80-0.95) and 
people with high intakes of marine omega-3 PUFAs had 15% lower risks (RR: 0.85; 
95% CI: 0.76-0.96) of BrCa compared to those with lower intake 59. Some studies 
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suggest that substitution of SFAs with MUFAs enhances glucose metabolism and 
post-prandial fat oxidation, thus increasing daily energy expenditure 1,2 
Ethanol and red wine 
In the traditional MSDP, moderate consumption of red wine is a habit during meals. 
Moderate intake is defined as two drinks per day for men (approximately 30g/d 
ethanol) and one drink for women (20g/d ethanol). The phenolic content of red 
wine and how it may protect against cancer is described in figure 4 and in the 
section of polyphenols. In the prospective cohort study by Van den Brandt & 
Schulpen, the beneficial effects of the MSDP were strongest for ER- BrCa in 
women with higher alcohol intake24. Similarly, in the PREDIMED trial post-
menopausal women in the MD+nuts group with higher alcohol intakes (>25g/d) 
had 66% reduced risks of BrCa compared with those in the low-fat diet group; 
women in the MD+nuts group with low alcohol intakes (<25g/d) had lower risk 
reductions for BrCa (16%)25. Nevertheless, the antioxidant and anti-inflammatory 
properties of red wine for cancer prevention are still controversial, particularly for 
BrCa and CRC. D’Allessandro et al found no association between moderate intake 
of red wine and CRC13, while a meta-analysis found that 10gr of ethanol per day 
increased the risk of CRC by 7%60 . Interestingly, people with positive family history 
of BrCa and low levels of folate who had the highest levels of alcohol intake were 
found to have increased risks of BrCa (HR=1.82, 95% CI: 1.06-3.12) 61. A potential 
biological plausibility for the relationship between alcohol and risk of BrCa is the 
increased levels of oestradiol from alcohol 62. In some studies, the effects of 
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alcohol on cancer risk were found to be modified by BMI and hormone receptor 
status. 63 found a step-wise increase in the RR of BrCa from 1.00 up to 1.32 with 
increasing category of alcohol whereas the results for more obese women were 
null. It is unknown whether the cancer protective effects of polyphenols in red wine 
may be compensated by the effects of ethanol content in the red wine.  Further 
studies investigating the effects of alcohol on cancer should take in consideration 
factors such as the pattern of drinking, the estimated level of underreporting of 
alcohol intake, the use of hormone replacement therapy (HRT) and the folate blood 
levels, genetics and having clear definitions about low and moderate consumption 
64. 
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Purpose and aims of the study 
Cancer is a major public health problem worldwide 1. Breast cancer (BrCa) is the 
second most commonly diagnosed tumor worldwide, with 67.5 cases per 100,000 
diagnosed among women in the US (2011-2015)97. One out of 7 women in the US 
will develop BrCa during her lifetime. The fourth most frequently diagnosed cancer 
is colorectal (CRC), with 39.4/100,000 new cases occurring in 2011-2015 in the 
US. Overall, the global cancer burden is influenced by both modifiable and non-
modifiable risk factors. Genetic factors are thought to explain approximately 5-10% 
of overall cancer cases while the remaining cases 90-95% of carcinogenesis are 
likely attributable to environmental and lifestyle factors 4. According to the World 
Health Organization (2018)95, the prevalence of obesity has nearly doubled since 
1975. A preponderance of the evidence suggests that obesity is an important 
independent risk factor for several cancers such as post-menopausal BrCa and 
CRC 6,32. It has been estimated that over the past decade, a 25% of cancer cases 
could be prevented by reducing obesity and improving health behaviors such as 
diets and physical activity 3. While diet has been extensively studied in the etiology 
of BrCa and CRC, evidence on specific foods and nutrients is rather weak and 
often conflicting 21,25. This inconsistency may be partly explained by the difficulty 
evaluating the independent effects of single foods or nutrients or the importance 
of the overall food matrix to cancer prevention. Thus, assessing dietary patterns 
may be essential to the successful prevention of BrCa and CRC 24,25,28.  
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Historically, populations living in the geographic area of near the Mediterranean 
Sea have had a lower incidence of cancer compared with those living in Northern 
Europe or the US, and this has been mainly attributed to the MSDP 15,27,31. The 
MSDP has been long described as a well-balanced diet with a predominance of 
plant-based food sources. However, the particular diet is somewhat variable 
across different Mediterranean cultures 6,15,53. The diet in Crete prior to1960 is 
often considered the model of a traditional MSDP. The Cretian diet is characterized 
by higher intakes of plant-based foods such as vegetables, fruits, legumes, nuts, 
and non-refined cereals and grain products (e.g. whole grains). Fish and poultry 
are consumed in moderation whereas consumption of red and processed meats, 
dairy products, refined grains, and sweets are limited. Olive oil and olives are the 
most common sources of fat. Red wine is consumed in moderation during meals 
and the population is generally quite physically active 4,6. In terms of nutrients, a 
MSDP is rich in polyphenols, phytochemicals, carotenoids, flavonoids, fiber, and 
the fatty acid profile is high in omega-3, MUFA, and arachidonic acid. This overall 
nutrient profile is thought to have antioxidant, anti-inflammatory, anti-obesity, 
antiproliferative, and anti-mutagenic properties 3,4,6,18,19,25,28,53.  
 
For nearly three decades, epidemiological evidence supports the health benefits 
of adherence to a MSDP in the primary and secondary prevention of non-
communicable chronic diseases such as cardiovascular disease and some 
neoplastic diseases 15,31,65. However, the relationships between MSDP and CRC 
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and BrCa are controversial. Investigators from A recent meta-analysis reported 
that the highest adherence to a MSDP was associated with a 14% lower risk of 
CRC and 6% lower risk of BrCa, findings that are similar to other studies 46,47,49,65. 
However, in meta-analyses by Schwingshackl et al the risk ratios from cohort 
studies found the effects of higher conformity to a MSDP on BrCa risk were non-
significant (RR=1.01, 95% CI:0.88-1.1627; RR=0.99, 95% CI:0.89-1.12, I2=33%35). 
These differences across studies could be due to non-comparable definitions of a 
MSDP, variations within and between different criterion-based MSDP scores, 
failure to separate pre- and post-menopausal BrCa, as well as different BrCa 
subtypes which may respond differently to lifestyle patterns 21. Another difference 
between MSDP scores across studies is the failure to consider the consumption 
of non-Mediterranean foods and the overconsumption of Mediterranean foods 
which may influence the adherence scores for the overall dietary pattern. A new 
MSDP score that addresses some of the limitations of previous scores has been 
developed by Rumawas et al., 2009 using data from the Framingham Heart study 
participants and will be used for the first time in this study to assess cancer-related 
outcomes. 
 
The primary aim of this prospective study is to examine the association between 
adherence to a MSDP and total, obesity-related, colorectal, as well as breast 
cancer risks in the Framingham Offspring (FOS) cohort. In secondary analyses for 
breast cancer, we will explore stratifying by hormone receptor status and 
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menopausal status. We will also examine whether these associations between 
MSDP and cancer risk are modified by anthropometric measures, lifestyle and 
dietary factors. We hypothesized that: a) higher adherence to a MSDP will be 
associated with a lower risk of total and obesity related cancers, particularly 
colorectal and breast cancer; b) The effects of higher MSDP score adherence on 
total and obesity-related cancers will be stronger among higher-risk individuals, 
such as those who are overweight or obese (vs. normal weight) (as measured by 
BMI or waist circumference) or sedentary; c) higher MSDP adherence will be more 
strongly associated with lower risk of ER-/PR- BrCa than any positive ER/PR BrCa. 
 
METHODS 
Study Sample 
The FOS began in 1971 with the recruitment of 5124 participants who were the 
adult children and spouses of participants in the original Framingham Heart 
Study66. After an initial 8-year interval between exams 1 and 2, subsequent 
examination cycles occurred at roughly 4-year intervals. At each examination visit, 
data collected from each participant include: anthropometric and urinary 
measures, demographic data, hematological samples, blood pressure, medical 
history and lifestyle habits (such as diet)67. The first complete food frequency 
questionnaire (FFQ) was administered at exam visit 5, which will serve as the 
baseline exam for the current analysis (1991-1995). Follow-up will continue until 
2013, the last year with available cancer follow-up data. Of the 3712 participants 
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attending the fifth examination, we excluded participants with: a) missing or invalid 
FFQ data (i.e., reported energy intakes of <600 kcal/d for all or >4000 kcal/d for 
women and >4200 kcal/d for men or 12 blank food items (n=361); b) history of 
prevalent cancer, except non-melanoma skin cancer cases (n=147); c)  age 
younger than 30 years old at baseline (n=4); d) missing MSDP score (n=1). A total 
of 3199 individuals were included in the analyses (Figure 5). 
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Total cancer risk or obesity 
related cancer (n=3199): 
Men (n=1456) 
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Figure 5: Flowchart of the study sample. 
FOS sample at exam 5 
(n=3712) 
Sample for analyses 
(n=3199) 
 
Participants excluded for: 
• Invalid FFQ (n=361) 
• Prevalent cancer (n=147) 
• Aged <30 years (n=4) 
• Missing MSDP score (n=1) 
FOS sample  
(n=5124) 
Colorectal cancer 
(n=3199) 
 
Breast cancer 
(n=1703) 
Post-menopausal BrCa 
(n=1690) 
 
Participants excluded: 
• Premenopausal 
BrCa cases 
(n=12) 
• Case with missing 
menopausal 
status (n=1)  
Participants excluded: 
• ER-/PR- BrCa 
cases (n=14) 
• Missing ERPR 
status (n=12) 
Any positive ER/PR 
BrCa (n=1677) 
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Assessment of adherence to MSDP 
Dietary data were collected via the Harvard 126-item semi-quantitative Food 
Frequency Questionnaire (FFQ)96. The FFQ was administered to participants via 
mail and participants were asked to bring the completed questionnaire to the 
examination appointment. The FFQ consists of a list of foods with standardized 
serving size and assesses the frequency of consumption during the previous year, 
ranging from “never or less than one serving per month” to “more than six 
servings/day”. Separate questions allowed participants to add up to 3 additional 
foods usually consumed that were not listed on the FFQ, as well as types of cold 
breakfast cereal and cooking oil usually used. Nutrient intakes per day were 
calculated by multiplying the frequency of consumption of each unit of food from 
the FFQ by the nutrient content of the specified portion 66. The FFQ has been 
validated for nutrients and foods in several previous publications 68,69. 
 
The individual’s adherence to a traditional MSDP, as defined by the Mediterranean 
diet pyramid 94 (Figure 2), was assessed using the MSDP score (MSDPS). The 
development of the MSDPS is discussed elsewhere 66  and is summarized below. 
The MSDPS is based on the recommended intake of 13 food groups in the 
Mediterranean diet pyramid (i.e., whole-grain cereals, fruit, vegetables, dairy, wine, 
fish, poultry, olives/legumes/nuts, potatoes, eggs, sweets, meat, and olive oil) and 
shown in Table 1. Each food item was categorized into 1 of these 13 food groups 
if the food or its characteristics approximated the principles of the traditional 
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Mediterranean diet. For example, while yams were not part of a traditional 
Mediterranean diet, other types of potatoes were. Thus, yams were classified in 
the potato category for the current score (Table 2, Classification of all foods). 
Except for olive oil, each food group was scored from 0 to 10 depending on the 
degree of correspondence with the recommendation (e.g., consuming 80% of the 
recommended servings would result in a score of 8). Exceeding the 
recommendations resulted in a lower score proportional to the degree of 
overconsumption (e.g., exceeding the recommendation by 80% would result in a 
score of 2). A negative score due to this overconsumption penalty was defaulted 
to zero. The olive oil score was categorized on the basis of the exclusive use of 
olive oil (score 10), the use of olive oil along with other vegetable oils (score 5), or 
no olive oil (score 0). The sum of the 13 component scores was standardized on 
a scale of 0–100 and weighted (from 0 to 1) by the proportion of energy intake 
attributed to the consumption of foods included in the Mediterranean diet pyramid. 
For instance, if an individual consumed 45% of energy from foods not included on 
the Mediterranean diet pyramid, the calculated weighting factor is 0.55. The 
weighting factor was used to account for foods that are not part or approximated 
to the principles of the Mediterranean diet pyramid (e.g., hot dogs, peanut butter, 
mayonnaise). The total MSDPS ranged from 0 to 100. The equation 66 used to 
calculate the MSDP score for each individual is the following along with an 
example below: 
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Example of calculation:  
 
Subject A: Standardized Score 
1) Achieved 6 of the 13 recommended components 
(score 10 per component) 
6 x 10=70 
2) Exceeded one recommendation by 40% 10-4=6 
3) Exceeded one recommendation by 130%       10-13= -3 defaulted to 0 
4) Consumed 50% of 2 recommendations 5 x 2 =10 
5) Consumed 30% of one recommendation 3 x 1=3 
6) Reported the use of olive oil along with other 
vegetable oils 
5 
 
Standardized sum=94 
7) Foods not included on the Mediterranean diet 
pyramid contributed 45% of the total energy intake  
Weighting factor = 0.55 
                                                                               MSDP score = 94 X 0.55 = 51.7 
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Table 1: Components of the MSDP score. Adopted from Rumawas et al 66. 
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Table 2: Foods commonly consumed in the U.S. according to the Mediterranean-
style dietary pattern food components. Adopted from Rumawas et al 66. 
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Cancer outcomes 
The diagnosis of incident cancer was made using a standardized protocol that has 
been discussed elsewhere70. The initial detection of a possible cancer case was 
made on the basis of self-report during structured interviews that took place at 
each yearly examination as well as surveillance of local hospital admissions and 
searches of the state health department's death records and the National Death 
Index71. Further, cancer cases were validated using clinical, laboratory and 
pathology reports 67.  Cancer diagnosis dates were derived from pathology reports. 
When a diagnosis occurred prior to pathology testing, or in few cases, when 
pathology results were not available, clinical records were used to identify the 
cancer diagnosis dates10. The cancer cases were defined as first primary-site 
malignant cancers International Classification of Diseases for Oncology code 
(ICD-O3 only), excluding non-melanoma skin cancer cases. Obesity-related 
cancer cases were selected based on previous literature10,72 and include female 
reproductive (post-menopausal breast, uterine/endometrial and ovarian), colon, 
rectum, stomach, liver, gallbladder, pancreas, kidney, thyroid, esophageal 
adenocarcinoma, leukemia, non-Hodgkin lymphoma and multiple myeloma. There 
were a total of 650 cancer cases of which 321 were obesity-related cancers. 
 
For the post-menopausal BrCa analysis, we excluded 12 women whose BrCa 
diagnosis date preceded their age of menopause and 1 case with unknown 
menopausal status (Figure 5). Among the eligible 1690 women, the post-
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menopausal BrCa cases were defined as women with BrCa diagnosis date later 
than or equal to their age of menopause (n=80). Total BrCa cases included both 
pre- and post-menopausal cases. 
 
We also classified BrCa by tumor hormone receptors defined by ER and PR status: 
any positive ER/PR status (including ER+/PR+, ER-/PR+, ER+/PR-) and negative 
ER/PR status (including ER-/PR-). In any positive ER/PR BrCa analysis, we 
excluded 12 cases with negative ER/PR BrCa and 14 cases with unknown ER/PR 
status. Among the eligible 1677 women, there were 67 cases with any positive 
ER/PR BrCa (n=67). 
 
Covariates 
Height and weight were measured with the subject standing, with shoes off, 
wearing only a hospital gown using a standard beam balance 10. The average of 
all measures of adult height prior to age 60 years was used in combination with 
exam-specific weight measures to calculate exam-specific body mass index (BMI). 
The use of mean height helps to reduce random measurement error and the effect 
of height loss after the age of 60 73. BMI (kg/m2) at exam 5 was calculated as the 
exam-specific weight (kg) divided by average measured adult height (meters, 
squared). 
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The physical activity index was created by multiplying self-reported hours of 
moderate and vigorous physical activity by an appropriate weight derived from 
oxygen consumption required for that level of activity and taking a sum of the two 
products (weight moderate activity plus weighted vigorous activity)72. The physical 
activity index is the mean of the values at exams 4 and 7. Parity was evaluated at 
exam 5 (yes/no) and determined based on the number of live births. Missing 
information for parity at exam 5 and/or inconsistencies between exams (1-5) were 
corrected using other available data from exams 1-4; in appropriate cases, the 
average (mode) number of reported live births from exams 1-4 were used for the 
parity variables. Education level at exam two was classified as follows: high school 
or less, some college, college or graduate degree. Missing data were substituted 
in this order: education level at exam 8, median education level for the subjects 
with the same occupation at exam 7, and sex-specific median education at exam 
2. Other covariates at exam 5 included: age (in years); sex; supplement use 
(including multivitamin and other supplement use: yes/no/missing); current 
cigarette smoking status (never, former, or current defined as 1 or more cigarettes 
per day); energy intake (kcal/d); alcohol intake (g/d); cigarette pack-years, waist 
circumference (cm) and waist-to-height ratio (WHtR, cm/m)  at exam 5 (with 
missing values substituted using the mean of each variable at exams 4 and 6). 
 
Menopausal status was determined by the presence or absence (6 months or 
more) of menstruation. We classified women as post-menopausal at the baseline 
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exam and separately at each follow-up exam (for use in time-dependent models). 
Pre-menopausal women were those who remained pre-menopausal up to the time 
of cancer diagnosis. Data substitution for missing menopausal status was carried 
out using non-missing information on use of hormone replacement therapy and 
menopause-related questions. Finally, age was used in the data substitution 
process, as follows: Two women missing information on menopausal status at 
baseline were classified as post-menopausal because their ages at exam 5 was 
above the median age of natural post-menopause and they reported using 
estrogen therapy at exam 5 or/and earlier. Data substitution was also carried out 
for women missing information on menopausal status at subsequent exams (e.g., 
did not attend exams). Those whose estimated age at time of the exam was at or 
above the median age at natural menopause were classified as post-menopausal 
(and those younger were classified as pre-menopausal). Inconsistencies in the 
report of menopausal status were similarly corrected. 
 
Age at menopause was classified as follows: pre-menopausal, premature post-
menopause (<45 years old), early menopause (45-48 years old), average age at 
menopause (48-52 years old) and late age at menopause (>52 years old) based 
on previous literature 74. Data substitution was carried out for 20 women with 
missing self-reported age at menopause using other data on menopausal status, 
use of estrogen or hormone replacement therapy, Age at menopause was also 
classified as natural or not natural (including surgical, radiation, chemotherapy use 
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and other).. In addition, sensitivity analysis (including and excluding substituted 
data) were carried out and supported the use of median for substituting the missing 
of age at menarche (n=248). 
 
Estrogen use (never/ever) was treated as a time-dependent variable and classified 
as never or ever users (prior to and including at baseline, and during the follow-up 
period). One hundred fourteen women who had missing information of estrogen 
use at some exams but who reported no use at other exams were treated as non-
users for the missing exams. For example, a woman who had a missing estrogen 
use at exam 4, but she was not a user at exam 1,2 and 3 and 5 and never started 
hormone replacement therapy, she would be substituted as non-user at exam 4 
and a never user at the baseline exam. 
 
Statistical Analysis 
Statistical analyses were conducted using SAS statistical software (version 9.4; 
SAS Institute, Cary, NC). The MSDPS was normally distributed and divided into 
tertile categories for analysis. The outcomes were incident total, obesity-related, 
colorectal, total breast, post-menopausal breast, and any positive ER/PR breast 
cancers. Incidence rates for each outcome were computed in each MSDP score 
tertile using person-years of follow-up time calculated from exam 5 to the first of 
the following events: occurrence of incident cancer, loss of follow-up, date of last 
exam or date of death. Cancer incidence rate was computed by dividing the 
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number of cancer cases by the total number of person-years in each MSDP score 
tertile. Cox-proportional hazards regression models were used to estimate 
adjusted HRs (and 95% CIs) for the occurrence of first cancer case. Wald tests for 
trend were also used to evaluate overall and sex-specific associations between 
MSDP scores cancer risks.  
 
All models (including overall and sex-specific) were adjusted for age (in years) and 
sex (for all subjects model). Next, we examined a predefined list of potential 
confounders and evaluated the extent to which they altered the age and sex 
adjusted-parameter estimates by approximately 10% or more, including: 1) body 
mass index (kg/m2,continuous), cigarette pack-years (continuous/day), physical 
activity (met/hours, continuous), diabetes (dichotomous yes/no), supplement use 
(never, ever users) for total cancer and obesity-related cancer risk analyses and 
2) WHtR height ratio (kg/m, continuous), cigarette pack-years (continuous/day), 
physical activity (met/hours, continuous), diabetes (yes/no, dichotomous), 
supplement use (never, ever users and missing) and age at menopause (defined 
as pre-menopause, <45 years old as premature menopause, 45-48 years old as 
early to middle, 48-52 as middle and 52+ years as late menopause) for BrCa, post-
menopausal BrCa and any positive ER/PR BrCa analyses. Factors, such as parity, 
educational level, alcohol intake, and age at menarche that were not confounders 
of the relationship between MSDP and cancer risk were not included in the final 
models.  
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Cox proportional hazard models were also used to explore whether the effects of 
the MSDP were modified by other factors. To optimize statistical power, we used 
sensitivity analysis to dichotomize the MSDP score. Based on these analyses, 
MSDP score was classified as follows: lower MSDP score (1st tertile (T1) of MSDP 
<18.99) vs. higher MSDP score (upper 2 tertiles of MSDP ≥18.99). Next, overall 
and sex-specific sensitivity analyses were used to determine the most appropriate 
cut-off values for potential effect modifiers including BMI, waist circumference, and 
WHtR. For the overall population and for women, BMI categories were <25 kg/m2 
vs ≥25 kg/m2 and for men <30 kg/m2 vs ≥30kg/m2 10,71. For women, waist 
circumference was categorized as high ≥91cm, middle 81-91cm and low <81cm 75 
and for men as high, >102cm; middle, 94-102cm; low <94cm. For the overall 
sample, WHtR was classified as low ≤0.51cm/m; middle 0.51-<0.58cm/m; and high 
≥0.58-0.95cm/m. For the sex-specific analysis we used two categories for WHtR 
≤0.51cm/m vs >0.51cm/m75, respectively. Alcohol intake was categorized as 
follows: non-drinkers (0g/d); light-to-moderate drinkers (0.1-13.99g/d) and heavier 
drinkers (≥14.00g/d) based on power considerations and sensitivity analyses. The 
evaluation of effect modification involved examining the stratum-specific HR 
estimates to determine whether the sum of the estimates deviated from an additive 
effect. The proportional hazards assumptions were tested in all models, and no 
violations of the assumption were found 
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RESULTS 
The mean of MSDP scores at exam 5 of the FOS was 22.43 (±7.26) (range 4.02-
50.95) (Figure 6) out of maximum possible score 100. Table 3 shows the subject 
characteristics according to MSDP score tertile categories. Compared with 
participants in the lowest tertile category of MSDP score, those in the highest tertile 
category were older, more likely to be women, had lower waist circumferences, 
higher educational level, and used more often dietary supplement. Table 4 
demonstrates that women in the higher MSDP score were more likely to be 
estrogen users and had older age at menopause compared to women in the lower 
MSDP categories. They were also less likely to be current smokers. MSDP score 
was positively associated with total energy intake. BMI, physical activity, WHtR 
were similar across the tertiles whereas alcohol intake declines (Table 3). 
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Figure 6: The distribution of the Mediterranean-Style Dietary Pattern Score 
(MSDPS) in the 5th examination of the Framingham Offspring Cohort (N=3199). 
Mean (± standard deviation): 22.43 (±7.26); median (min, max): 22.15 (4.01, 
50.94); 5th, 25th, 75th and 95th percentiles: 11.0, 17.23, 22.15 and 34.9. 
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Table 3:  Baseline characteristics (mean (±SD), or n (column percentage) 
according to tertiles of MSDP score: the Framingham Offspring Cohort 
 MSDPS tertile categories  
 T1 T2 T3 p -value 
Characteristic (n=3199) n=1066 n=1067 n=1066  
Sex    <.0001 
Men 590 (55.4) 492 (46.1) 414 (38.8)  
Women 476 (44.7) 575 (53.9) 652 (61.2)  
Age (years) 52.9 (± 9.5) 55.0 (± 9.9) 55.3 (± 9.5) <.0001 
Age at diagnosis (years) 65.7 (± 9.1) 68.0 (± 8.7) 67.3 (± 9.0) 0.02 
Education    <.0001 
<=High School 478 (44.8) 399 (37.4) 343 (32.2)  
Some college  291 (27.3) 312 (29.2) 331 (31.1)  
College, Graduate degree 297 (27.9) 356 (33.4) 392 (36.8)  
BMI (kg/m2) 27.5 (± 5.0) 27.4 (± 4.9) 27.1 (± 5.0) 0.24 
Waist (cm) 93.8 (± 14.2) 93.0 (± 14.2) 91.3(± 14.5) 0.0002 
Waist-to-height ratio (kg/m) 0.5 (± 0.1) 0.5 (± 0.1) 0.6 (± 0.1) 0.07 
Cigarette smoking      <.0001 
Never 317 (29.7) 359 (33.7) 412 (38.7)  
Former 448 (42.0) 515 (48.4) 523 (49.1)  
Current 301 (28.2) 191 (17.9) 130 (12.2)  
Pack years (geometric mean 
IQR) 
20.4 (± 0.9) 16.21(± 0.8) 12.0 (± 0.6) <.0001 
Calories (kcal/d) 1743.4 
(± 651.2) 
1878.9 
(± 614.0) 
1975.5 
(± 583.4) 
<.0001 
Alcohol consumption (g/d) 
geometric mean IQR) 
8.10 (± 0.4) 7.30 (± 0.3) 6.61 (± 0.3) 0.32 
Supplement use    <.0001 
No 787 (75.1) 759 (72.6) 672 (64.3)  
Yes 261 (24.9) 286 (27.4) 373 (35.7)  
Physical activity (METs/hour) 14.4 (±9.2) 14.5 (±8.1) 15.1 (±8.0) 0.10 
Diabetes    0.21 
No 1001 (94.3) 989 (93.0) 979 (92.4)  
Yes 61 (5.7) 74 (7.0) 81 (7.6)  
MSDP tertiles : T1: 4.0184-18.9890, T2: 18.9895-25.3215, T3: 25.3240-50.9495.  
P values were generated from analysis of variance for continuous and chi-square for categorical 
variables. 
Abbreviations:  MSDP, Mediterranean style dietary pattern; T, Tertile; METs, Metabolic 
equivalents, IQR: Interquartile Range 
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Table 4:  Baseline characteristics (mean (±SD), or n (column percentage) in 
women according to tertiles of MSDP score: the Framingham Offspring 
Cohort 
 MSDPS tertile categories  
 T1 T2 T3 p - value 
Characteristics (n=1703) n=476 n=575 n=652  
Age at menarche (yrs) 12.8 (± 1.5) 12.9 (± 1.6) 12.8 (± 1.4) 0.63 
Menopausal status    0.21 
Premenopausal 82 (17.2) 95 (16.6) 90 (13.8)  
Postmenopausal 300 (63.0) 382 (66.6) 424 (65.0)  
Age at menopause (years, 
median IQR) 
48.0 (± 6.0) 49.0 (± 7.0) 49.0 (± 7.0) 0.09 
Natural menopause  49.3 (± 4.4) 49.5 (± 3.9) 50.4 (± 3.9) 0.001 
Not Natural menopause 41.1 (± 6.6) 41.3 (± 6.5) 42.1 (± 6.8) 0.40 
Estrogen Use (exams 1-7)    0.001 
   Never 304 (63.9) 379 (65.9) 376 (57.7)  
Ever 172 (36.1) 196 (34.1) 276 (42.3)  
Parity    0.31 
   No 73 (15.3) 73 (12.7) 81 (12.4)  
Yes 403 (84.7) 502 (87.3) 571 (87.6)  
P values were generated from analysis of variance for continuous and chi-square for categorical 
variables. Abbreviations:  MSDP, Mediterranean style dietary pattern; T, Tertile; IQR: Interquartile 
Range 
 
 
Total cancer 
Of the 3199 men and women aged 30-82 years at exam 5 of the FOS, 650 
developed cancer (Table 5). Overall, those in the highest MSDP score tertile 
category had the lowest cancer incidence rate 11.49 per 1000 person-years of 
follow-up compared with 12.18 and 14.02 cancer cases per 1000 person-years in 
the middle and lowest MSDP score tertile categories, respectively. After adjusting 
for age, body mass index, pack-years, physical activity, diabetes, supplement use 
at exam 5 and sex, men and women in the highest and middle tertile of MSDP 
score had 15% and 16% lower risk of total cancer compared to lowest tertile of 
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MSDP score, respectively (HRtertile3: 0.85, 95% CI: 0.70-1.03; HRtertile2: 0.84, 95% 
CI: 0.68-1.03). Analysis stratifying by sex demonstrated that the positive relations 
of adherence to MSDP score with total cancer risk were significantly stronger in 
women than in men. For women, results from the age adjusted model were similar 
to the fully adjusted model. In particular, women in the medium and highest 
MSDPS score tertile categories had 31% (95% CI: 0.50-0.94) and 27% lower 
cancer risks (95% CI: 0.55-0.96) compared to those in the lowest MSDP score 
tertile, respectively. 
 
Table 6 presents the independent and combined associations of adherence to 
MSDP score with anthropometric and lifestyle characteristics on total cancer risk. 
Subjects with higher adherence to the MSDP had a lower overall cancer risk, 
regardless of their BMI status. However, among women, those who were lean (BMI 
<25) had a greater reduction in cancer risk associated with higher adherence to 
the MSDP suggesting the presence of some degree of effect modification in the 
sex-specific analyses. There was also some evidence of effect modification of the 
MSDP effects by waist and WHtR, particularly among women. In fact, when 
stratified by sex, the protective effects of higher MSDP score adherence on total 
cancer risk were generally driven by the observed effects in women.  
 
Waist circumference and WHtR among women had minimal effect on total cancer 
risk in those with low adherence to a MSDP. In contrast, women with high 
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adherence to a MSDP had 23% (HR 0.77; 95% CI: 0.55-1.09) and 31% (HR: 0.69; 
95% CI: 0.47-1.00) lower risks of total cancer in the categories of high and low 
WHtR, respectively. Effects in men were much weaker. 
  
We then explored potential effect modification by alcohol intake (Table 6). We 
observed that non-drinkers had lower risks of total cancer regardless of MSDP 
score. However, those consuming up to 14g of alcohol per day and who adhered 
more to the MSDP had the lowest risk of developing total cancer (HR: 0.62 95% 
CI: 0.47-0.81). Physical activity was found not to be an effect modifier in the 
association of MSDP and cancer risk. In fact, more active individuals with low 
adherence to a MSDP had 44% higher risks of total cancer. In addition, non-
smoking individuals in the higher MSDP adherence had 50% lower cancer risk 
(95% CI: 0.38-0.69). This effect was approximately additive (37% lower risk from 
non-smoking alone plus 12% lower risk associated with MSDP adherence alone). 
Finally, the stratified analyses related to estrogen use suggest that estrogen use 
alone had no effect on cancer risk while MSDP adherence was once again 
protective. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSDP scores for overall: T1: 4.0184-18.9890; T2:18.9895-25.3215; T3: 25.3240-50.9495, MSDP scores for men: T1: 4.02-18.98; 
T2: 18.99-25.31; T3: 25.32-47.66, MSDP scores for women: T1: 4.05-18.99; T2: 19.00-25.32; T3: 25.33-50.95 
Abbreviations:  MSDP, Mediterranean style dietary pattern; HR, hazard ratio;  CI, confidence interval; T, Tertile; Ref, reference 
category; # Number. 
a The analysis was adjusted for age and sex (for all subjects model). 
b Adjusted for age, body mass index(kg/m2), pack-years, physical activity (met/hours), diabetes (yes/no), supplement use (never, 
ever users, missing) at exam 5 and sex (for all subjects model). 
Table 5: Hazard ratios for total cancer, according to MSDP score tertiles. 
 #Subjects PY #cases Rate/1000py HR CI (95%)
a HR CI (95%)b 
Overall (n=3199)       
MSDPS tertiles       
T1  239 1066 17044 14.02 1 (Ref) 1 (Ref) 
T2  210 1067 17245 12.18 0.82 (0.68-0.99)  0.85(0.70-1.03) 
T3  201 1066 17488 11.49 0.78 (0.65-0.95) 0.84 (0.68-1.03) 
P-trend     0.01 0.08 
Men (n=1496)       
MSDPS tertiles       
T1  147 590 9154 16.06 1 (Ref) 1 (Ref) 
T2  129 492 7504 17.19 0.91 (0.72-1.16) 0.94 (0.74-1.21) 
T3  101 414 6398 15.79 0.80 (0.62-1.03) 0.90 (0.68-1.18) 
P-trend     0.09 0.43 
Women (n= 1703)       
MSDPS tertiles       
T1  92 476 7890 11.66 1 (Ref) 1 (Ref) 
T2  81 575 9742 11.66 0.68 (0.50-0.92) 0.69 (0.50-0.94) 
T3  100 652 11089 8.31 0.73 (0.55-0.96) 0.73 (0.54-0.99) 
P-trend     0.04 0.05 
4
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Table 6: Effect modification of the association between adherence to MSDP and 
total cancer risk in women and men in the Framingham Offspring Study according to 
lifestyle, treatment and behavioral characteristics. 
 
 
#Subjects PY #cases 
Rate/ 
1000py 
HR CI (95%) 
BMI (kg/m2) n=3193a      
Lower Adherence       
BMI≥25  716 11242 167 14.85 1.00 (Ref.) 
BMI<25  350 5827 71 12.18 1.03 (0.77-1.37) 
Higher adherence       
BMI≥25 1357 21796 286 13.12 0.87 (0.71-1.06) 
BMI<25  770 12843 125 9.73 0.83 (0.65-1.07) 
BMI (kg/m2) women 
n=1698 a 
     
Lower Adherence       
BMI≥25  250 4101 47 11.46 1.00 (Ref.) 
BMI<25  225 3784 44 11.63 1.13 (0.74-1.73) 
Higher adherence       
BMI≥25 657 10970 110 10.03 0.83 (0.58-1.19) 
BMI<25  566 9802 71 7.24 0.68 (0.46-1.00) 
BMI (men), n=1495 a 
     
Lower Adherence       
BMI≥30 163 2468 40 16.21 1.00 (Ref.) 
BMI<30  428 6716 107 15.93 0.95 (0.65-1.39) 
Higher adherence       
BMI≥30 243 3612 67 18.55 0.95 (0.63-1.44) 
BMI<30 661 10256 163 15.89 0.88 (0.61-1.27) 
Waist categories (cm, 
women, n=1700)b 
     
Lower Adherence       
High (≥91) 172 2741 37 13.50 1.00 (Ref.) 
Middle (81-91) 114 1870 22 11.77 0.99 (0.55-1.76) 
Low (<81) 189 3275 32 9.77 0.93 (0.54-1.62) 
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Higher adherence       
High (≥91) 425 6873 76 11.06 0.76 (0.51-1.14) 
Middle (81-91) 343 5936 47 7.92 0.66 (0.41-1.07) 
Low (<81) 457 8002 58 7.25 0.66 (0.40-1.09) 
      
Waist categories (cm) 
men, n=1496b 
    
 
Lower Adherence       
High (>102) 200 2955 57 19.29 1.00 (Ref.) 
Middle (94-102) 177 2740 43 15.69 0.65 (0.42-1.02) 
Low (<94) 215 3492 47 13.46 0.67 (0.41-1.10) 
Higher adherence       
High (>102) 303 4497 86 19.12 0.80 (0.56-1.14) 
Middle (94-102) 284 4425 68 15.37 0.63 (0.42-0.95) 
Low (<94) 317 4946 76 15.36 0.71 (0.45-1.12) 
Waist-to-height ratio 
Height Ratio (cm/m, 
n=3194)a 
     
Lower Adherence       
High (≥0.58-0.95) 384 5885 94 15.97 1.00 (Ref.) 
Middle (0.51-<0.58) 341 5407 77 14.24 0.87 (0.64-1.20) 
Low (≤0.51) 340 5777 66 11.42 1.07 (0.77-1.50) 
Higher adherence       
High (≥0.58-0.95) 681 10443 157 15.03 0.84 (0.64-1.10) 
Middle (0.51-<0.58) 724 11671 153 13.11 0.88 (0.67-1.16) 
Low (≤0.51) 724 12564 101 8.04 0.74(0.55-1.00) 
Waist-to-height ratio 
Height Ratio (cm/m) 
women, n =1699) a 
     
Lower Adherence       
High (>0.51) 264 4285 52 12.13 1.00 (Ref.) 
Low (≤0.51) 210 3600 38 10.56 1.05 (0.68-1.61) 
Higher adherence       
High (>0.51) 680 11248 112 9.96 0.77 (0.55-1.09) 
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Low  (≤0.51) 545 9562 69 7.22 0.69 (0.47-1.00) 
Waist-to-height ratio 
Height Ratio (cm/m, 
men,n=1495)a 
     
Lower Adherence       
High (>0.51) 483 7379 124 16.80 1.00 (Ref.) 
Low (≤0.51) 108 1805 23 12.74 1.10 (0.69-1.74) 
Higher adherence       
High (>0.51) 758 11444 204 17.83 0.97 (0.76-1.23) 
Low (≤0.51) 146 2424 26 10.73 0.83 (0.54-1.28) 
Alcohol intake (g/d, 
n=3199)c 
     
Lower Adherence       
≥14  289 4366 87 19.93 1.00 (Ref.) 
0.1-13.99 468 7672 96 12.51 0.86 (0.64-1.16) 
Non-drinkers 311 5038 56 11.11 0.63 (0.44-0.90) 
Higher adherence       
≥14  470 7391 112 15.15 0.86 (0.64-1.15) 
0.1-13.99 1103 18352 188 10.24 0.62 (0.47-0.81) 
Non-drinkers 558 8956 111 12.39 0.70 (0.52-0.94) 
Physical Activity 
(mets/hour n=3126)d 
     
Lower Adherence       
T1 (0.00- 9.80) 371 5892 70 11.88 1.00 (Ref.) 
T2 (9.80-16.90) 325 5262 71 13.49 1.13 (0.81-1.59) 
T3 (17.00- 57.00) 340 5441 92 16.91 1.44 (1.05-1.98) 
Higher adherence       
T1 (0.00- 9.80) 624 10092 107 10.60 0.90 (0.66-1.23) 
T2 (9.80-16.90) 743 12361 137 11.08 0.99 (0.73-1.33) 
T3 (17.00- 57.00) 723 11608 164 14.13 1.12 (0.84-1.50) 
Cigarette smoking 
statuse 
     
Lower Adherence       
Current 301 4708 76 16.14 1.00 (Ref.) 
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Former 450 7090 105 14.81 0.72 (0.53-0.97) 
Non-smokers 317 5279 58 10.99 0.63 (0.44-0.89) 
Higher adherence       
Current 321 5076 73 14.38 0.88 (0.64-1.23) 
Former 1036 16615 210 12.64 0.60 (0.46-0.79) 
Non-smokers 771 12959 128 9.88 0.51 (0.38-0.69) 
Estrogen use 
(n=1703)c 
     
Lower Adherence       
User 172 2906 33 11.36 1.00 (Ref.) 
Non-user 304 4984 59 11.84 1.02 (0.66-1.58) 
Higher adherence       
User 472 8182 67 8.19 0.68 (0.44-1.05) 
Non-user 755 12649 114 9.01 0.75 (0.50-1.12) 
Lower adherence defined as MSDP <18.99 and higher adherence as ≥18.99 
Abbreviations:  MSDP, Mediterranean style dietary pattern; HR, hazard ratio; CI, confidence 
interval; T, Tertile; Ref, reference category; Mets/hour, metabolic equivalents per hours; 
a Adjusted for age, pack-years, physical activity (met/hours), diabetes (yes/no), supplement use 
(never, ever, missing) at exam 5 and sex (all subjects model). 
b Adjusted for age, hip girth (cm), pack-years, physical activity (met/hours), diabetes (yes/no), 
supplement use (never/ever) at exam 5. 
c Adjusted for age, BMI (kg/m2), pack-years, physical activity (met/hours), diabetes (yes/no), 
supplement use (never/ever) (never/ever) at exam 5 and sex (all subjects model). 
d Adjusted for age, BMI (kg/m2), pack-years, diabetes (yes/no), supplement use (never/ever) at 
exam 5 and sex. 
e Adjusted for age, BMI (kg/m2), physical activity (met/hours), diabetes (yes/no), supplement use 
(never/ever) at exam 5 and sex
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Obesity-related cancer 
In Table 7, we show the results from the same analyses done previously but this 
time using obesity-related cancer as the outcome of interest. Similar but slightly 
weaker inverse associations were found between adherence to MSDP and 
obesity-related cancer risk for the pooled sample and also among women. 
Adjusting for additional covariates, as described above for the analysis of total 
cancer, people in the highest MSDP score tertile had 20% lower risk of obesity-
related cancer compared to those in the lowest MSDP score tertile category 
(HRtertile3: 0.80, 95% CI:0.60-1.07). For women, the highest and medium MSDP 
score tertile categories were associated with lower obesity-related cancer 
incidence rates, i.e., 6.50 and 6.00 per 1000 person-years of follow-up, 
respectively compared with 7.74 obesity-related cancer cases per 1000 person-
years in the lowest MSDP score tertile category. In the fully adjusted model among 
women, both higher MSDP tertile categories exerted similar obesity-related cancer 
protective effects versus the lowest MSDP tertile; higher adherence to the MSDP 
was associated with about 25% non-statistically significant reduced risk (HRtertile3: 
0.73, 95% CI: 0.51-1.05; HRtertile2: 0.76, 95% CI: 0.53-1.09) of obesity-related 
cancer. 
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Table 8 explores possible effect modification of the association between adherence to 
MSDP and obesity-related cancer risk in women and men in the FOS according to lifestyle, 
treatment, and behavioral characteristics. For the pooled sample, we observed some 
evidence of effect modification (on an additive scale) of the higher adherence MSDP 
effects on obesity related cancer risk by BMI and WHtR. When stratified by sex, the 
protective effects of higher MSDP adherence were stronger and evident among women 
only. In particular, women with lean BMI in the higher MSDP score category had 42% 
(95% CI 0.37-0.91) lower obesity-related cancer risk compared to obese or overweight 
women in the lower MSDP score category. Similarly, low WHtR height ratio and higher 
MSDP adherence in women were associated with 38% (95% CI 0.39-0.98) lower obesity 
related cancer incidence (vs. those with high WhtR and lower MSDP score). Interestingly, 
similar strong protective effects of higher MSDP score were equally observed among 
women with middle and low waist circumference, but not high (vs. those in the lower MSDP 
score and high waist circumference, respectively, HRhigh 0.59, 95% CI 0.35-1.01; HRlow 
0.59, 95% CI 0.35-0.97).  Surprisingly again, those consuming up to 14g of alcohol per 
day and who adhered more to the MSDP had the lowest and strongest risk of developing 
obesity-related cancer. 
  
 
MSDP scores for overall: T1: 4.0184-18.9890; T2:18.9895-25.3215; T3: 25.3240-50.9495, MSDP scores for men: T1: 4.02-18.98; 
T2: 18.99-25.31; T3: 25.32-47.66, MSDP scores for women: T1: 4.05-18.99; T2: 19.00-25.32; T3: 25.33-50.95 
Abbreviations:  MSDP, Mediterranean style dietary pattern; HR, hazard ratio; CI, confidence interval; T, Tertile; Ref, 
reference category, #Number. 
a Adjusted for age and sex (for all subjects model). 
b Adjusted for age, body mass index(kg/m2), pack-years, physical activity (met/hours), diabetes (yes/no), supplement use 
(never, ever users, missing) at exam 5 and sex (for all subjects model). 
 
Table 7: Hazard ratios for obesity-related cancer, according to MSDP score tertiles. 
  #Cases #Subjects PY Rate/1000py HR (95% CI)
a HR (95% CI)b 
Overall (n=3199)       
MSDPS tertiles        
T1  108 1066 17841.04 6.05 1 (Ref) 1 (Ref) 
T2 105 1067 17907.03 5.86 0.87 (0.66-1.14) 0.86 (0.65-1.13) 
T3 108 1066 18152.16 5.95 0.85 (0.65-1.11) 0.80 (0.60-1.07) 
P-trend     0.18 0.13 
Men (n=1496)       
MSDPS tertiles        
T1  46 590 9834.35 4.68 1 (Ref) 1 (Ref) 
T2  46 492 8076.45 5.70 1.04 (0.69-1.57) 1.01 (0.66-1.55) 
T3  35 414 6919.51 5.06 0.90 (0.58-1.40) 0.93 (0.58-1.48) 
P-trend     0.65 0.76 
Women (n= 1703)       
MSDPS tertiles       
T1  62 476 8006.69 7.74 1 (Ref) 1 (Ref) 
T2  59 575 9830.58 6.00 0.75 (0.52-1.07) 0.76 (0.53-1.09) 
T3  73 652 11232.65 6.50 0.79 (0.56-1.11) 0.73 (0.51-1.05) 
P-trend     0.21 0.10 
5
4
 
  55 
Table 8: Modification of the association between adherence to MSDP and obesity-
related cancer risk in women and men in the Framingham Offspring Study according 
to lifestyle, treatment, and behavioral characteristics. 
 
 
#Subjec
ts 
PY #cases 
Rate/ 
1000py 
HR CI (95%) 
BMI (kg/m2) n=3193a 
     
Lower Adherence       
BMI≥25 716 11887 72 6.06 1.00 (Ref.) 
BMI<25 350 5980 35 5.85 0.92 (0.61-1.40) 
Higher adherence       
BMI≥25 1357 22771 146 6.41 0.89 (0.66-1.19) 
BMI<25 770 13196 67 5.08 0.73 (0.51-1.04) 
BMI (kg/m2), women 
n=1698 a      
Lower Adherence       
BMI≥25 250 4150 35 8.43 1.00 (Ref.) 
BMI<25 225 3852 26 6.75 0.85 (0.51-1.43) 
Higher adherence       
BMI≥25 657 11110 83 7.47 0.80 (0.53-1.21) 
BMI<25 566 9894 49 4.95 0.58 (0.37-0.91) 
BMI (kg/m2), men 
n=1495 a 
     
Lower Adherence       
BMI≥28 266 4315 26 6.03 1.00 
BMI<28 325 5550 20 3.60 0.55 (0.30-1.00) 
Higher adherence       
BMI≥28 406 6690 40 5.98 0.75 (0.44-1.26) 
BMI<28 498 8272 41 4.96 0.71 (0.42-1.19) 
Waist categories (cm), 
women, n=1700b      
Lower Adherence       
High (≥91) 172 2788 26 9.33 1.00 (Ref.) 
Middle (81-91) 114 1884 16 8.49 0.97 (0.51-1.84) 
Low (<81) 189 3330 19 5.71 0.70 (0.38-1.28) 
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Higher adherence       
High (≥91) 425 6968 57 8.18 0.78 (0.48-1.26) 
Middle (81-91) 343 5973 33 5.52 0.59 (0.35-1.01) 
Low (<81) 457 8101 42 5.18 0.58 (0.35-0.97) 
Waist categories (cm) 
men, n=1496 b 
     
Lower Adherence       
High (>102) 200 3207 23 7.17 1.00 (Ref.) 
Middle (94-102) 177 2993 8 2.67 0.32 (0.14-0.73) 
Low (<94) 215 3669 15 4.09 0.57 (0.29-1.11) 
Higher adherence       
High (>102) 303 4841 35 7.23 0.72 (0.41-1.25) 
Middle (94-102) 284 4809 19 3.95 0.43 (0.23-0.81) 
Low (<94) 317 5312 27 5.08 0.67 (0.37-1.19) 
Waist-to-height ratio 
Height Ratio (cm/m) 
n=3194)a 
     
Lower Adherence       
High (≥0.58-0.95) 384 6211 49 7.89 1.00 (Ref.) 
Middle (0.51-<0.58) 341 5722 22 3.84 0.51(0.30-0.86) 
Low (≤0.51) 340 5934 35 5.90 0.83(0.53-1.30) 
Higher adherence       
High (≥0.58-0.95) 681 10941 86 7.86 0.79(0.54-1.14) 
Middle (0.51-<0.58) 724 12255 70 5.71 0.71(0.48-1.03) 
Low (≤0.51) 724 12808 57 4.45 0.55(0.37-0.83) 
Waist-to-height ratio 
Height Ratio (cm/m), 
women n=1699a          
Lower Adherence         
High (>0.51) 264 4341 36 8.29 1.00 (Ref.) 
Low (≤0.51) 210 3661 24 6.56 0.93 (0.55-1.59) 
Higher adherence       
High (>0.51) 680 11372 85 7.47 0.83 (0.56-1.25) 
Low (≤0.51) 545 9670 47 4.86 0.62 (0.39-0.98) 
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Waist-to-height ratio 
Height Ratio (cm/m), 
men n=1495a  
     
Lower Adherence       
High (>0.51) 483 7972 37.00 4.64 1.00 (Ref.) 
Low (≤0.51) 108 1893 9.00 4.76 1.31 (0.60-2.83) 
Higher adherence       
High (>0.51) 758 12415 73.00 5.88 1.07 (0.71-1.62) 
Low (≤0.51) 146 2548 8.00 3.14 0.80 (0.37-1.74) 
Alcohol intake (g/d, 
n=3199)c 
    
 
Lower Adherence       
≥14 289 4767 29 6.08  1.00 (Ref.) 
0.1-13.99 468 7973 44 5.52  0.92 (0.57-1.48) 
Non-drinkers 311 5134  35 6.82 0.84 (0.50-1.40) 
Higher adherence       
≥14  470 7787 55 7.06 1.05 (0.67-1.66) 
0.1-13.99 1103 18959 101 5.33 0.68 (0.44-1.05) 
Non-drinkers 558 9280 57 6.14 0.73 (0.46-1.17) 
Estrogen use 
(n=1703)c 
     
Lower Adherence       
User 172 2930 27 9.21 1.00 (Ref.) 
Non-user 304 5076 35 6.89 0.70 (0.42-1.17) 
Higher adherence       
User 472 8245 51 6.19 0.61 (0.38-0.99) 
Non-user 755 12818 81 6.32 0.60 (0.38-0.94) 
Lower adherence defined as MSDP<18.99 and higher adherence as ≥18.99 
Abbreviations:  MSDP, Mediterranean style dietary pattern; HR, hazard ratio; CI, confidence 
interval; T, Tertile; Ref, reference category; Mets/hour, metabolic equivalents per hours 
a Adjusted for age, pack-years, physical activity (met/hours), diabetes (yes/no), supplement use 
(never, ever, missing) at exam 5 and sex (for all subjects model). 
b Adjusted for age, hip girth (cm), pack-years, physical activity (met/hours), diabetes (yes/no), 
supplement use (never, ever, missing) at exam 5. 
c Adjusted for age, body mass index(kg/m2), pack-years, physical activity (met/hours), diabetes 
(yes/no), supplement use (never, ever, missing) at exam 5 and sex (for all subjects model) 
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Breast Cancer 
Adherence to the Mediterranean dietary pattern was associated with a statistically 
significant lower risk of BrCa, including total BrCA, post-menopausal BrCa, and 
positive ER/PR cases. (Table 9). The effects were slightly stronger among post-
menopausal cases than for total cases. Additional adjustment for potential 
confounders (age, WHtR height ratio, pack-years, physical activity, diabetes, 
supplement use at exam 5, and age at menopause) did not result in noticeable 
changes in the estimates. A dose-response relation was observed; with lower BrCa 
risk associated with increasing adherence to the Mediterranean diet pattern. There 
was 42% lower risks of total BrCa and any positive ER/PR BrCa in tertile 3 of 
MSDP adherence. However, the larger number of total cases yielded greater 
precision for assessing risk of total BrCa.  
 
  
Table 9: Hazard ratios for total breast cancer, post-menopausal breast cancer, and any positive ER/PR breast  
cancer according to MSDP score tertiles. 
Abbreviations:  MSDP, Mediterranean style dietary pattern; HR, hazard ratio; CI, confidence interval; T, Tertile; Ref,  
reference     category; ER/PR, estrogen receptor/progesterone receptor. #Number.  
a Adjusted for age. b Adjusted for age, waist-to-height ratio height ratio (kg/m), pack-years, physical activity (met/hours),  
diabetes (yes/no), supplement use (never, ever, missing) at exam 5 and age at menopause (defined as pre-menopause,  
<45 years old as premature menopause, 45-48 years old as early to middle, 48-52 as middle and 52+ years as late 
menopause).
  #Cases #Subjects PY Rate/1000py HR (95% CI)
a HR (95% CI)b 
Breast cancer (n=1703)       
MSDPS tertiles       
T1 (4.05-18.99) 35 476 8181 4.28 1 (Ref) 1 (Ref) 
T2 (19.00-25.32) 29 575 10041 2.89 0.67 (0.41-1.09) 0.68 (0.40-1.14) 
T3 (25.33-50.95) 29 652 11546 2.51 0.57 (0.35-0.93) 0.58 (0.34-0.98) 
P-trend     0.03 0.04 
Post-menopausal breast 
cancer (n=1690) 
      
MSDPS tertiles       
T1 (4.05-18.99) 30 471 8135 3.69 1 (Ref) 1 (Ref) 
T2 (19.00-25.32) 26 572 10019 2.60 0.67 (0.40-1.14) 0.70 (0.41-1.21) 
T3 (25.33-50.95) 24 647 11493 2.09 0.53 (0.31-0.91) 0.51 (0.29-0.91) 
P-trend     0.02 0.02 
Any positive ER/PR 
breast cancer (n=1677)       
MSDPS tertiles       
T1 (4.05-18.99) 25 466 8107 3.08 1 (Ref) 1 (Ref) 
T2 (19.00-25.32) 20 566 9960 2.01 0.64 (0.35-1.15) 0.63 (0.34-1.15) 
T3 (25.33-50.95) 22 642 11493 1.91 0.60 (0.34-1.06) 0.58 (0.31-1.06) 
P-trend     0.08 0.08 
5
9
 
  
Colorectal cancer 
In these analyses, we found no association between adherence to MSDP and colorectal cancer risk. 
 
 
Table 10: Hazard ratio of colorectal cancer, according to MSDP score tertiles in age-adjusted and 
multivariable-adjusted analyses, the Framingham Offspring Study 
 
 
 
MSDP scores for overall: T1: 4.0184-18.9890; T2:18.9895-25.3215; T3: 25.3240-50.9495, Abbreviations:  MSDP, 
Mediterranean style dietary pattern; HR, hazard ratio;  CI, confidence interval; T, Tertile; Ref, reference category, #, 
Number. 
a Adjusted for age and sex. 
b Adjusted for age, body mass index (kg/m2) , pack-years, physical activity (met/hours), diabetes (yes/no), supplement 
use (never, ever, missing) at exam5 and sex (for all subjects model
  #Cases #Subjects   PY Rate/1000py HR (95% CI)
a HR (95% CI)b 
Overall (n=3199)        
MSDPS tertiles       
T1  24 1066 18452 1.30 1 (Ref) 1 (Ref) 
T2  24 1067 18408 1.30 0.93 (0.53-1.65) 0.96 (0.53-1.72) 
T3  21 1066 18794 1.12 0.81 (0.45-1.47) 0.90 (0.48-1.67)    
P-trend      0.50   0.73 
6
0
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DISCUSSION 
 
This is the first long-term population-based study using the MSDP score developed 
by Rumawas et al (2009) to assess the adherence to a Mediterranean-style diet in 
relation to cancer risk66. We observed that consuming a diet consistent with the 
principles of the MSDP was favorably associated with reductions in total cancer 
and obesity-related cancer risks among FOS participants aged 30 years or older 
and especially among women.  
 
In this study, higher adherence to MSDP was somewhat more strongly protective 
against total cancer risk among lower-risk individuals such as those who were 
leaner (BMI <25), drank less alcohol (<14 g/d), and did not currently smoke 
cigarettes. To the best of our knowledge, this is the first study demonstrating a 
protective effect of higher MSDP conformity with obesity-related cancer risk. The 
inverse association between MSDP and total and obesity-related cancer 
occurrence in women was modified by anthropometric measures of body fat such 
as BMI, waist circumference, and WHtR. In addition, in this study, adherence to 
the MSDP was inversely associated with both total and ER/PR positive BrCa risk, 
and that this effect was slightly more protective for post-menopausal cases.  
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In this cohort, we found that individuals who had the highest MSDP score had 
healthier lifestyle characteristics such as a lower waist circumference and a lower 
likelihood of smoking. Other studies have also found that those with a higher 
MSDP score were less likely to smoke37 but this is not the case in all population 
groups41. We observed no difference in baseline BMI across the three MSDP 
tertiles as has been seen in many 21,44,50,76,77 but not all previous studies 37,46,78. 
 
Two previous studies have reported beneficial effects of the MD on total cancer 
incidence. The multicenter European prospective cohort study (EPIC) followed 
142,605 men and 335,873 women for a median time of 8.7 years, and found that 
the highest MD score category (Trichopoulou et al., 20051) was associated with 
7% reductions in total cancer risk in both men and women (HRmen: 0.93, 95% CI: 
0.88-0.99; HRwomen: 0.93, 95% CI: 0.89-0.96)30. Further stratification by location 
(Mediterranean vs. non-Mediterranean countries), showed no substantial 
difference in total cancer risk reductions per 2-point increase in MD score. This 
suggests that the cancer-protective effects of the MD are also relevant to non-
Mediterranean populations, a finding that was also seen in our results, using a 
sample of the US population. Given the high incidence of cancer in the United 
States over the past few years 1,2, these findings are particularly important.  
 
These results in the Framingham cohort were stronger than those found in the 
large EPIC study. This could have resulted from the use of different MSDP scoring 
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methods. Specifically, the EPIC study applied a diet score that was determined by 
cut-off points based on sex-specific population medians of nutrient intakes rather 
than comparing actual intakes with recommended intakes from the MD pyramid as 
is done in the current study. In addition, the EPIC study included total alcohol rather 
than red wine, and total MUFAs (which could be derived from meat rather than 
olive oil as the main source of unsaturated fat). Further, a sub-cohort of the EPIC 
study including the center from Greece, found that adherence to MSDP was 
associated with 22% lower risk (95% CI 0.64–0.94) overall, with stronger effects 
among women (HR: 0.73, 95% CI: 0.56–0.96) than men (HR: 0.83, 95% CI: 0.63–
1.09), a trend that was similar to our results in Framingham.  
 
In our effect modification analyses, higher adherence to MSDP was protective 
against total and obesity-related cancer among women regardless of their baseline 
waist circumference or WHtR (low or middle WHtR, for total cancer). To the best 
of our knowledhe, no studies have assessed effect modification of the MSDP on 
cancer risk by baseline central adiposity (waist circumference, WhtR). We also 
found weak lower risks of total and obesity-related cancers among 
overweight/obese women with higher MSDP score while those who were lean (BMI 
<25kg/m2) had greater and strong reductions. Very few studies examined the effect 
modification of baseline BMI on cancer risk and MSDP, classified in 
categories42,23,79  (instead of analyzed as point increments80–83). A case-control 
study  found that obese women in the highest MSDP quintile had greater 
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reductions in BrCa risk than those in the lowest quintile, while overweight and 
normal-weight women had only small reductions in risk42. In addition, individuals 
with BMI≥25kg/m2 and higher MD score category had 24% lower BrCa risk  (95% 
CI: 0.61–0.94)  compared to those in the lower MD score23, while other study found 
no effect modification by BMI in women48. Overall, our results along with the 
previous limited literature suggests that baseline BMI and simple anthropometric 
measures of central adiposity (e.g., waist circumference, WhtR), may play a key 
role in modifying the association between a MSDP and cancer risk.  
 
We observed that non-drinkers had lower risks of total cancer regardless of MSDP 
score. However, those consuming up to 14g of alcohol per day and who adhered 
more to the MSDP had the lowest risk of developing total and obesity related 
cancer. While there is some evidence that high alcohol consumption is a risk factor 
for cancer development, particularly BrCa63 and CRC 60, other epidemiologic 
evidence suggests that light to moderate alcohol intake and especially red wine 
intake in the context of MSDP may be protective against cancer risk. Here again, 
most of the previous studies assessed alcohol intake as an effect modifier on the 
relationship of specific cancer and MD adherence which was analyzed as point 
increments instead of categorical, and therefore caution should be taken when 
compared to our results. Overall, most these previous studies have found more 
pronounced MSDP cancer protective effects among high-risk individuals such as 
those with higher (more than 1 drink/d) rather than lower alcohol consumption. For 
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every 1-point increase in MD score, women with less than 1 drink/d had a 15% 
lower risk of head and neck cancer, whereas higher alcohol consumption (1-3 
drinks/d) was related to greater risk reductions. A similar great lower risk was seen 
in men with >3 drinks/d, but lower alcohol consumption had no effect on cancer, 
per 1-point MD increment 83. Furthermore, In the PREDIMED trial, post-
menopausal women in the MD+nuts group with ~>2 drinks/d (>25g/d alcohol) had 
66% reduced risk of BrCa compared with those in the low-fat diet; whereas women 
with less than 2 drinks/d (<25g/d) had a 16% reduced risk25. Other studies found 
no effect modification by alcohol intake for the relationship between MD and breast 
or pancreatic cancer risks 24,79.   
 
Several biological mechanisms could explain the cancer protective effects of red 
wine.  Red wine is high in polyphenols, especially resveratrol and quercetin which 
have been found to inhibit COX1, COX2, and lipoxygenase (LOX). Reductions in 
COX activity reduces the levels of arachidonic acid, leukotrienes, prostaglandins, 
and fatty acid derived inflammatory mediators that can promote tumorigenesis 54. 
Further, it is possible cancer protective effects of polyphenols in red wine, and 
especially in the context of MSDP, may compensate for the adverse effects of 
ethanol in the red wine. 
 
Our results suggest an inverse relationship between adherence to the MSDP and 
BrCa risk especially in post-menopausal women, and the hazard ratios tended to 
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decrease in a linear fashion. Higher conformity to MD has been associated with 
lower rates of overall BrCa in many observational studies (case-control and 
cohort), and differences were noted between molecular subtypes (defined by 
hormone receptor status), and menopausal status. Other studies failed to verify 
such an association. For the first time, the meta-analysis by Schwingshackl et al., 
(2017) found that the risk of BrCa was lower by 6% when adhering to MSDP by 
pooling seven cohorts (RRcohort=0.94, 95% CI:0.90-0.99) with very low 
heterogeneity (I2=8%). However, the beneficial effects of high adherence to a 
MSDP (vs. lowest MSDP) were observed among post-menopausal but not pre-
menopausal women1. Our results were inconsistent with those from a prospective 
cohort study by Cade et al in which maximal adherence to MSDP was not 
associated with post-menopausal BrCa risk (HR=1.30, 95% CI:0.83-2.05), but was 
associated with significant reductions in pre-menopausal BrCa risk (HR: =0.65, 
95% CI:0.42-1.02) 37. The EpiGEICAM case-control study found inverse 
associations in both subgroups38. We had limited power to assess the association 
of MSDP on pre-menopausal BrCa risk due to the small number of cases. Overall, 
most studies 38–40 conclude that MSDP seems to be more protective against post-
menopausal than pre-menopausal BrCa, a finding that could be attributed to anti-
obesity effects of the MSDP since higher body fat is a strong risk factor of  post-
menopausal BrCa.  
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Further, we demonstrated that higher MSDP adherence seems to be protective 
against any positive ER/PR BrCa (including ER+/PR+, ER-/PR+, ER+/PR-). 
However, the sample size was small, and we also had limited power to assess the 
effects of negative ER/PR BrCa or the individual risks of ER+/PR-, ER-/PR+, 
ER+/PR+ breast cancers. Our results were in conflict with the ones in the meta-
analysis by Schwingshackl et al36 and in some individual epidemiologic studies 
43,44  showing no association of MD with any positive ER/PR BrCa risk, while lower 
risks were seen in ER-/PR- BrCa with higher MD score. On the other hand, a few 
studies reported an association of higher conformity to MSDP and lower incidence 
rates of ER+/PR+ BrCa, in which estrogen metabolism is involved 24,41,45.  Given 
this, some of the beneficial MSDP effects could be a consequence of certain 
nutrients in the MSDP that have been shown to reduce endogenous estrogen 
production and increase sex-hormone binding globulin levels, thus decreasing 
circulating levels of estrogen and reducing the risk of BrCa. However, these 
subtype findings are based on a limited number of studies with very small sample 
sizes, and thus further studies are warranted.  
 
Some previous studies found no association between MSDP and BrCa. In meta-
analyses by Schwingshackl et al., in 2014 and 2015, the authors found no 
association between higher conformity to MSDP and BrCa 27,35. To date, there is 
only one randomized clinical trial, the PREDIMED study, which shows promising 
results with respect to the effects of MD and prevention of post-menopausal BrCa 
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25. The MD+ olive oil group had a 68% reduction (95% CI: 0.13-0.79) and the MD+ 
nuts groups a 41% (95% CI 0.26-1.35) reduction in risk of post-menopausal BrCa 
compared with the control group. One major limitation of this study lies in the small 
number of incident BrCa cases (n=35) and that analyses were not stratified by 
molecular BrCa subtypes.  
 
The unique mixture of foods and nutrients in the MSDP pattern may act 
synergistically to protect against the development or spread of certain cancers 30. 
Overall, the MSDP is rich in polyphenols, phytochemicals, carotenoids, flavonoids, 
resveratrol, fiber, and its fatty acid profile is high in omega-3 and MUFA. This 
overall nutrient profile is thought to have antioxidant, anti-inflammatory, 
antiproliferative and anti-mutagenic properties 3,4,6,18,19,25,28,53. In addition, the high 
fiber, polyphenol, and MUFA content, as well as the consumption of plant-based 
foods, could explain some of the obesity-protective effects of MSDP on cancer 
development6. There is some evidence suggesting that higher adherence to MSDP 
is inversely associated with overall adiposity and central obesity6,41,84 . Despite the 
higher fat content in the MSDP, dietary interventions based on this diet have shown 
a low to modest weight loss and lower abdominal adiposity 85–87. Central adiposity 
and obesity are well-established risk factors for cancer development, and 
observational cohort studies have shown that intentional weight loss is associated 
with reductions in cancer incidence (especially breast cancer) 88–90. Modest levels 
of intentional weight loss resulted in consistent reductions in estrogen levels and 
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biomarkers of inflammation (such as TNF‐α and IL‐6)85. Taken together, these 
data may support the hypothesis that an improvement in or prevention of obesity 
or metabolic dysfunction, may be part of the mechanism by which MSDP lowers 
cancer risk84.  For instance, a prospective cohort study recruiting individuals 
without diabetes mellitus from the FOS, found that higher (vs. lower) MSDP scores 
were associated with lower waist circumference, HOMA-IR, fasting plasma 
glucose and triglycerides, and higher HDL cholesterol (mean follow-up time of 7 
years) 87. Also, those in the highest quintile category of MSDP score also had the 
lowest cumulative incidence of metabolic syndrome (30.1%, 95% CI: 25.8, 34.4%). 
One clinical trial demonstrated that people with metabolic syndrome assigned to 
the MD group had a 2 cm greater decrease in waist circumference and 2.8 (-5.1 to 
-0.5) kg greater weight loss than those in the control group (prudent diet)85. Overall 
clinical and epidemiologic evidence suggests that a MSDP is associated with lower 
adiposity and improvement in metabolic traits, findings that may in part explain the 
cancer-protective effects of this diet pattern.  
 
Although the current and previous evidence suggests MSDP adherence is 
protective against cancer, we should note that there is no consensus on the 
definition of a MSDP due to wide dietary variations across different cultures, 
religions, ethnicities and social-economic structures existing among and within the 
different countries (Demetriou et al., 2012b; Grosso et al., 2013; Kwan et al., 2017). 
Adherence to a Mediterranean style diet has been assessed in previous studies 
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using a variety of criterion-based diet scores such as the modified MD, alternate 
MD and the relative MD index 4. Therefore a number of quantitative and qualitative 
aspects of the diet must be considered when comparing studies on MSDP and 
cancer outcomes due to the variability within and between the different dietary 
indices, including the number of dietary components included, the weighting 
strategies, and the range of the scores used 41,53.  
 
The strengths of our study include its prospective design and that it is a relatively 
large cohort with carefully-adjudicated cancer outcomes. All cancer cases were 
validated through a careful review of medical records using standardized 
procedures 70. In addition, confounding effects may be minimized as a result of 
careful systematic collection of potential confounding variables. Nonetheless, 
residual confounding is always a possibility in this and other clinical and 
epidemiologic studies. Finally, the direct measures of adiposity (rather than using 
self-reported data) are important strengths of the study.  
 
There are several limitations in this study as well. First, the MSDPS assigned equal 
weight to each of its food components, and therefore, the associations in this study 
were also based on the assumption that each food group in the Mediterranean-
style dietary pattern contributes equally to the outcomes. Nonetheless, the cancer-
protective effects of Mediterranean-style diet, are most likely due to the synergistic 
effects of the diet as a whole, comprised of all the nutrients rather than the effects 
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of individual food components 30. The second limitation of this work concerns the 
limited distribution of the scores for the overall diet pattern in this study. Of the 
possible maximum MSDPS of 100, the highest score achieved in this study 
population was 50.95. Although a higher value of the MSDPS reflects greater 
conformity to a Mediterranean-style dietary pattern, an individual’s diet will not 
conform entirely to the Mediterranean-style dietary pattern unless the person 
achieves the maximum score of 100. Further, the current MSDPS is based on a 
FFQ; since the component scores are standardized to energy intake and since 
energy intake is not measured well with a FFQ, this is likely to be an important 
source of error. However, earlier validation studies of the Harvard FFQ showed 
that many of the foods included in the MSDPS were adequately captured on the 
FFQ based on correlations with diet records 91. Another important limitation of this 
study is the limited power associated with small numbers of subjects in some of 
the individual cancer types. There were also insufficient numbers of some cancers 
(e.g., liver, pancreas, gallbladder) to allow for the estimation of effects on these 
individual cancer types. In addition, FOS subjects were exclusively Caucasian, so 
these results may not be representative of risks in a multiethnic population. Finally, 
although the use of oral contraceptives can influence the effects of MSDP23 on 
cancer risk (especially breast) 92, we were unable to comment on those, because 
such data were not available in this data set. 
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CONCLUSION 
This is the first large prospective cohort study to show that consumption of a 
Mediterranean-style diet may be one effective dietary strategy for protecting 
against obesity-related cancers especially among women. We also found inverse 
associations between adherence to a MSDP and total and breast cancer risk. In 
this study, the protective effects of higher MSDP adherence on total cancer were 
strong regardless of the waist circumference, WHtR, and estrogen use in women. 
Furthermore, higher adherence to a MSDP was somewhat more strongly 
protective against total cancer risk among those who were leaner (BMI<25kg/m2), 
drank less alcohol (<14 g/d), and did not currently smoke cigarettes. Therefore, 
adhering to a MSDP might contribute to cancer prevention in a US population. 
However, further studies are warranted to confirm the potential benefit of a 
Mediterranean-style diet in mitigating cancer development.  
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